Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer

Cancer Letters

Volumn 344, Issue 2, 2014, Pages 157-165

  Van Maerken, Tom ^a   Rihani, Ali ^a   Van Goethem, Alan ^a   De Paepe, Anne ^a   Speleman, Frank ^a   Vandesompele, Jo ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

MDM2; Nutlin; P53; Pediatric tumors; Targeted therapy

Indexed keywords

NUTLIN 3; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILD; CHILDHOOD CANCER; EWING SARCOMA; HUMAN; LOSS OF FUNCTION MUTATION; MEDULLOBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RETINOBLASTOMA; RHABDOMYOSARCOMA; SHORT SURVEY; TUMOR CELL; TUMOR SUPPRESSOR GENE; WILD TYPE;

MDM2; NUTLIN; P53; PEDIATRIC TUMORS; TARGETED THERAPY;

ANIMALS; CHILD; GENES, P53; HUMANS; IMIDAZOLES; NEOPLASMS; PIPERAZINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893695754     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.11.002     Document Type: Review

References (118)

1. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
2. Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol. 2010, 20:14-24.
3. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
4. Manfredi J.J. The MDM2-p53 relationship evolves: MDM2 swings both ways as an oncogene and a tumor suppressor. Genes Dev. 2010, 24:1580-1589.
5. Wade M., Li Y.C., Wahl G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer 2013, 13:83-96.
6. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
7. Kusafuka T., Fukuzawa M., Oue T., Komoto Y., Yoneda A., Okada A. Mutation analysis of p53 gene in childhood malignant solid tumors. J. Pediatr. Surg. 1997, 32:1175-1180.
8. Imamura J., Bartram C.R., Berthold F., Harms D., Nakamura H., Koeffler H.P. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res. 1993, 53:4053-4058.
9. Komuro H., Hayashi Y., Kawamura M., Hayashi K., Kaneko Y., Kamoshita S., Hanada R., Yamamoto K., Hongo T., Yamada M., Tsuchida Y. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res. 1993, 53:5284-5288.
10. Vogan K., Bernstein M., Leclerc J.M., Brisson L., Brossard J., Brodeur G.M., Pelletier J., Gros P. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 1993, 53:5269-5273.
11. Kato M.V., Shimizu T., Ishizaki K., Kaneko A., Yandell D.W., Toguchida J., Sasaki M.S. Loss of heterozygosity on chromosome 17 and mutation of the p53 gene in retinoblastoma. Cancer Lett. 1996, 106:75-82.
12. Schlamp C.L., Poulsen G.L., Nork T.M., Nickells R.W. Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells. J. Natl. Cancer Inst. 1997, 89:1530-1536.
13. waf-1 expression correlates with apoptosis or cell survival in poorly differentiated, but not well-differentiated, retinoblastomas. Cancer Res. 2001, 61:3157-3163.
14. Gokgoz N., Wunder J.S., Mousses S., Eskandarian S., Bell R.S., Andrulis I.L. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 2001, 92:2181-2189.
15. Kovar H., Auinger A., Jug G., Aryee D., Zoubek A., Salzer-Kuntschik M., Gadner H. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993, 8:2683-2690.
16. Huang H.Y., Illei P.B., Zhao Z., Mazumdar M., Huvos A.G., Healey J.H., Wexler L.H., Gorlick R., Meyers P., Ladanyi M. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J. Clin. Oncol. 2005, 23:548-558.
17. Taylor A.C., Shu L., Danks M.K., Poquette C.A., Shetty S., Thayer M.J., Houghton P.J., Harris L.C. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med. Pediatr. Oncol. 2000, 35:96-103.
18. Saylors R.L., Sidransky D., Friedman H.S., Bigner S.H., Bigner D.D., Vogelstein B., Brodeur G.M. Infrequent p53 gene mutations in medulloblastomas. Cancer Res. 1991, 51:4721-4723.
19. Pfaff E., Remke M., Sturm D., Benner A., Witt H., Milde T., von Bueren A.O., Wittmann A., Schöttler A., Jorch N., Graf N., Kulozik A.E., Witt O., Scheurlen W., von Deimling A., Rutkowski S., Taylor M.D., Tabori U., Lichter P., Korshunov A., Pfister S.M. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J. Clin. Oncol. 2010, 28:5188-5196.
20. Wada M., Bartram C.R., Nakamura H., Hachiya M., Chen D.L., Borenstein J., Miller C.W., Ludwig L., Hansen-Hagge T.E., Ludwig W.D., Reiter A., Mizoguchi H., Koeffler H.P. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993, 82:3163-3169.
21. Malkin D., Sexsmith E., Yeger H., Williams B.R., Coppes M.J. Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res. 1994, 54:2077-2079.
22. Litofsky N.S., Hinton D., Raffel C. The lack of a role for p53 in astrocytomas in pediatric patients. Neurosurgery 1994, 34:967-972.
23. Rasheed B.K.A., McLendon R.E., Herndon J.E., Friedman H.S., Friedman A.H., Bigner D.D., Bigner S.H. Alterations of the TP53 gene in human gliomas. Cancer Res. 1994, 54:1324-1330.
24. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
25. Secchiero P., di Iasio M.G., Gonelli A., Zauli G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr. Pharm. Des. 2008, 14:2100-2110.
26. Shen H., Maki C.G. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr. Pharm. Des. 2011, 17:560-568.
27. Saha M.N., Qiu L., Chang H. Targeting p53 by small molecules in hematological malignancies. J. Hematol. Oncol. 2013, 6:23.
28. Kojima K., Konopleva M., McQueen T., O'Brien S., Plunkett W., Andreeff M. MDM2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006, 108:993-1000.
29. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B.T., Qing W., Packman K., Myklebost O., Heimbrook D.C., Vassilev L.T. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 2006, 103:1888-1893.
30. Moskovits N., Kalinkovich A., Bar J., Lapidot T., Oren M. P53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 2006, 66:10671-10676.
31. Secchiero P., Corallini F., Gonelli A., Dell'Eva R., Vitale M., Capitani S., Albini A., Zauli G. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ. Res. 2007, 100:61-69.
32. Secchiero P., Corallini F., Rimondi E., Chiaruttini C., di Iasio M.G., Rustighi A., Del Sal G., Zauli G. Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood 2008, 111:1287-1294.
33. Bálint E., Bates S., Vousden K.H. MDM2 binds p73α without targeting degradation. Oncogene 1999, 18:3923-3929.
34. Zeng X., Chen L., Jost C.A., Maya R., Keller D., Wang X., Kaelin W.G., Oren M., Chen J., Lu H. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 1999, 19:3257-3266.
35. Martin K., Trouche D., Hagemeier C., Sørensen T.S., La Thangue N.B., Kouzarides T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995, 375:691-694.
36. LaRusch G.A., Jackson M.W., Dunbar J.D., Warren R.S., Donner D.B., Mayo L.D. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1α and HDM2. Cancer Res. 2007, 67:450-454.
37. Lau L.M.S., Nugent J.K., Zhao X., Irwin M.S. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008, 27:997-1003.
38. Ambrosini G., Sambol E.B., Carvajal D., Vassilev L.T., Singer S., Schwartz G.K. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007, 26:3473-3481.
39. Ozenne P., Eymin B., Brambilla E., Gazzeri S. The ARF tumor suppressor: structure, functions and status in cancer. Int. J. Cancer 2010, 127:2239-2247.
40. Van Maerken T., Rihani A., Dreidax D., De Clercq S., Yigit N., Marine J.C., Westermann F., De Paepe A., Vandesompele J., Speleman F. Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3. Mol. Cancer Ther. 2011, 10:983-993.
41. Li X., Gilkes D., Li B., Cheng Q., Pernazza D., Lawrence H., Lawrence N., Chen J. Abnormal MDMX degradation in tumor cells due to ARF deficiency. Oncogene 2012, 31:3721-3732.
42. Markowski D.N., Helmke B.M., Radtke A., Froeb J., Belge G., Bartnitzke S., Wosniok W., Czybulka-Jachertz I., Deichert U., Bullerdiek J. Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium. BMC Womens Health 2012, 12:2.
43. Thompson T., Tovar C., Yang H., Carvajal D., Vu B.T., Xu Q., Wahl G.M., Heimbrook D.C., Vassilev L.T. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 2004, 279:53015-53022.
44. Tang Y., Zhao W., Chen Y., Zhao Y., Gu W. Acetylation is indispensable for p53 activation. Cell 2008, 133:612-626.
45. Cheung N.K.V., Dyer M.A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat. Rev. Cancer 2013, 13:397-411.
46. Linabery A.M., Ross J.A. Trends in childhood cancer incidence in the US (1992-2004). Cancer 2008, 112:416-432.
47. Li J., Thompson T.D., Miller J.W., Pollack L.A., Stewart S.L. Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics 2008, 121:e1470-e1477.
48. ARF pathway abnormalities in relapsed neuroblastoma. Clin. Cancer Res. 2010, 16:1108-1118.
49. ARF-MDM2-p53 axis. Cell Death Differ. 2009, 16:1563-1572.
50. Barbieri E., Mehta P., Chen Z., Zhang L., Slack A., Berg S., Shohet J.M. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol. Cancer Ther. 2006, 5:2358-2365.
51. Chen L., Malcolm A.J., Wood K.M., Cole M., Variend S., Cullinane C., Pearson A.D., Lunec J., Tweddle D.A. P53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle 2007, 6:2685-2696.
52. Van Maerken T., Speleman F., Vermeulen J., Lambertz I., De Clercq S., De Smet E., Yigit N., Coppens V., Philippé J., De Paepe A., Marine J.C., Vandesompele J. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 2006, 66:9646-9655.
53. Gamble L.D., Kees U.R., Tweddle D.A., Lunec J. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Oncogene 2012, 31:752-763.
54. Becker K., Marchenko N.D., Maurice M., Moll U.M. Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ. 2007, 14:1350-1360.
55. Peirce S.K., Findley H.W. High level MYCN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity. Oncol. Rep. 2009, 22:1443-1449.
56. Petroni M., Veschi V., Prodosmo A., Rinaldo C., Massimi I., Carbonari M., Dominici C., McDowell H.P., Rinaldi C., Screpanti I., Frati L., Bartolazzi A., Gulino A., Soddu S., Giannini G. MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response. Mol. Cancer Res. 2011, 9:67-77.
57. Veschi V., Petroni M., Cardinali B., Dominici C., Screpanti I., Frati L., Bartolazzi A., Gulino A., Giannini G. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by Nutlin-3 in neuroblastoma cells. PLoS One 2012, 7:e49139.
58. Ribas J., Boix J., Meijer L. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis. Exp. Cell Res. 2006, 312:2394-2400.
59. Patterson D.M., Gao D., Trahan D.N., Johnson B.A., Ludwig A., Barbieri E., Chen Z., Diaz-Miron J., Vassilev L., Shohet J.M., Kim E.S. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis 2011, 14:255-266.
60. Michaelis M., Rothweiler F., Klassert D., von Deimling A., Weber K., Fehse B., Kammerer B., Doerr H.W., Cinatl J. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res. 2009, 69:416-421.
61. Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M., Löschmann N., Voges Y., Breitling R., von Deimling A., Rödel F., Weber K., Fehse B., Mack E., Stiewe T., Doerr H.W., Speidel D., Cinatl J. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011, 2:e243.
62. Van Maerken T., Ferdinande L., Taildeman J., Lambertz I., Yigit N., Vercruysse L., Rihani A., Michaelis M., Cinatl J., Cuvelier C.A., Marine J.C., De Paepe A., Bracke M., Speleman F., Vandesompele J. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J. Natl. Cancer Inst. 2009, 101:1562-1574.
63. Dimaras H., Kimani K., Dimba E.A.O., Gronsdahl P., White A., Chan H.S.L., Gallie B.L. Retinoblastoma. Lancet 2012, 379:1436-1446.
64. Laurie N.A., Donovan S.L., Shih C.S., Zhang J., Mills N., Fuller C., Teunisse A., Lam S., Ramos Y., Mohan A., Johnson D., Wilson M., Rodriguez-Galindo C., Quarto M., Francoz S., Mendrysa S.M., Guy R.K., Marine J.C., Jochemsen A.G., Dyer M.A. Inactivation of the p53 pathway in retinoblastoma. Nature 2006, 444:61-66.
65. Popowicz G.M., Czarna A., Wolf S., Wang K., Wang W., Dömling A., Holak T.A. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 2010, 9:1104-1111.
66. Hu B., Gilkes D.M., Farooqi B., Sebti S.M., Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J. Biol. Chem. 2006, 281:33030-33035.
67. Patton J.T., Mayo L.D., Singhi A.D., Gudkov A.V., Stark G.R., Jackson M.W. Levels of HDMX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006, 66:3169-3176.
68. Wade M., Wong E.T., Tang M., Stommel J.M., Wahl G.M. Hdmx modulates the outcome of P53 activation in human tumor cells. J. Biol. Chem. 2006, 281:33036-33044.
69. Elison J.R., Cobrinik D., Claros N., Abramson D.H., Lee T.C. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch. Ophthalmol. 2006, 124:1269-1275.
70. Zhang F., Tagen M., Throm S., Mallari J., Miller L., Guy R.K., Dyer M.A., Williams R.T., Roussel M.F., Nemeth K., Zhu F., Zhang J., Lu M., Panetta J.C., Boulos N., Stewart C.F. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab. Dispos. 2011, 39:15-21.
71. Brennan R.C., Federico S., Bradley C., Zhang J., Flores-Otero J., Wilson M., Stewart C., Zhu F., Guy K., Dyer M.A. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res. 2011, 71:4205-4213.
72. Das M., Sahoo S.K. Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One 2012, 7:e32920.
73. Kitagawa M., Aonuma M., Lee S.H., Fukutake S., McCormick F. E2F-1 transcriptional activity is a critical determinant of MDM2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 2008, 27:5303-5314.
74. Ritter J., Bielack S.S. Osteosarcoma. Ann. Oncol. 2010, 21(Suppl. 7):vii320-vii325.
75. Mirabello L., Troisi R.J., Savage S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance. Epidemiol. End Results Program, Cancer 1973, 115(2009):1531-1543.
76. Momand J., Jung D., Wilczynski S., Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998, 26:3453-3459.
77. Duhamel L.A., Ye H., Halai D., Idowu B.D., Presneau N., Tirabosco R., Flanagan A.M. Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes. Histopathology 2012, 60:357-359.
78. Wang B., Fang L., Zhao H., Xiang T., Wang D. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells. Acta Biochim. Biophys. Sin. 2012, 44:685-691.
79. Tovar C., Graves B., Packman K., Filipovic Z., Higgins B., Xia M., Tardell C., Garrido R., Lee E., Kolinsky K., To K.H., Linn M., Podlaski F., Wovkulich P., Vu B., Vassilev L.T. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res. 2013, 73:2587-2597.
80. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
81. Ohnstad H.O., Paulsen E.B., Noordhuis P., Berg M., Lothe R.A., Vassilev L.T., Myklebost O. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer 2011, 11:211.
82. Hori T., Kondo T., Kanamori M., Tabuchi Y., Ogawa R., Zhao Q.L., Ahmed K., Yasuda T., Seki S., Suzuki K., Kimura T. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett. 2010, 287:98-108.
83. Zhang F., Throm S.L., Murley L.L., Miller L.A., Zatechka D.S., Guy R.K., Kennedy R., Stewart C.F. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem. Pharmacol. 2011, 82:24-34.
84. Aziz M.H., Shen H., Maki C.G. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene 2011, 30:4678-4686.
85. Balamuth N.J., Womer R.B. Ewing's sarcoma. Lancet Oncol. 2010, 11:184-192.
86. Janknecht R. EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 2005, 363:1-14.
87. Pishas K.I., Al-Ejeh F., Zinonos I., Kumar R., Evdokiou A., Brown M.P., Callen D.F., Neilsen P.M. Nutlin-3a is a potential therapeutic for Ewing sarcoma. Clin. Cancer Res. 2011, 17:494-504.
88. Sonnemann J., Palani C.D., Wittig S., Becker S., Eichhorn F., Voigt A., Beck J.F. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. Eur. J. Cancer 2011, 47:1432-1441.
89. Nakatani F., Ferracin M., Manara M.C., Ventura S., Del Monaco V., Ferrari S., Alberghini M., Grilli A., Knuutila S., Schaefer K.L., Mattia G., Negrini M., Picci P., Serra M., Scotlandi K. MiR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J. Pathol. 2012, 226:796-805.
90. Dasgupta R., Rodeberg D.A. Update on rhabdomyosarcoma. Semin. Pediatr. Surg. 2012, 21:68-78.
91. Miyachi M., Kakazu N., Yagyu S., Katsumi Y., Tsubai-Shimizu S., Kikuchi K., Tsuchiya K., Iehara T., Hosoi H. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin. Cancer Res. 2009, 15:4077-4084.
92. Crawford J.R., MacDonald T.J., Packer R.J. Medulloblastoma in childhood: new biological advances. Lancet Neurol. 2007, 6:1073-1085.
93. Hoffman S., Schellinger K.A., Propp J.M., McCarthy B.J., Campbell R.T., Davis F.G. Seasonal variation in incidence of pediatric medulloblastoma in the United States, 1995-2001. Neuroepidemiology 2007, 29:89-95.
94. Dolecek T.A., Propp J.M., Stroup N.E., Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012, 14(Suppl. 5):v1-v49.
95. Ghassemifar S., Mendrysa S.M. MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells. Neurosci. Lett. 2012, 513:106-110.
96. Künkele A., De Preter K., Heukamp L., Thor T., Pajtler K.W., Hartmann W., Mittelbronn M., Grotzer M.A., Deubzer H.E., Speleman F., Schramm A., Eggert A., Schulte J.H. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro Oncol. 2012, 14:859-869.
97. Buss M.C., Read T.A., Schniederjan M.J., Gandhi K., Castellino R.C. HDM2 promotes WIP1-mediated medulloblastoma growth. Neuro Oncol. 2012, 14:440-458.
98. Lu X., Ma O., Nguyen T.A., Jones S.N., Oren M., Donehower L.A. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007, 12:342-354.
99. Zhou M., Yeager A.M., Smith S.D., Findley H.W. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood 1995, 85:1608-1614.
100. Gustafsson B., Stål O., Gustafsson B. Overexpression of MDM2 in acute childhood lymphoblastic leukemia. Pediatr. Hematol. Oncol. 1998, 15:519-526.
101. Zhou M., Gu L., Abshire T.C., Homans A., Billett A.L., Yeager A.M., Findley H.W. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia 2000, 14:61-67.
102. Marks D.I., Kurz B.W., Link M.P., Ng E., Shuster J.J., Lauer S.J., Carroll D., Brodsky I., Haines D.S. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 1997, 15:1158-1162.
103. Gustafsson B., Axelsson B., Gustafsson B., Christensson B., Winiarski J. MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr. Hematol. Oncol. 2001, 18:497-508.
104. Moorman A.V., Ensor H.M., Richards S.M., Chilton L., Schwab C., Kinsey S.E., Vora A., Mitchell C.D., Harrison C.J. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010, 11:429-438.
105. Hof J., Krentz S., van Schewick C., Korner G., Shalapour S., Rhein P., Karawajew L., Ludwig W.D., Seeger K., Henze G., von Stackelberg A., Hagemeier C., Eckert C., Kirschner-Schwabe R. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 2011, 29:3185-3193.
106. Gu L., Zhu N., Findley H.W., Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008, 22:730-739.
107. Zhu N., Gu L., Li F., Zhou M. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol. Cancer Ther. 2008, 7:1101-1109.
108. Carol H., Reynolds C.P., Kang M.H., Keir S.T., Maris J.M., Gorlick R., Kolb E.A., Billups C.A., Geier B., Kurmasheva R.T., Houghton P.J., Smith M.A., Lock R.B. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 2012, 60:633-641.
109. Kojima K., Konopleva M., Samudio I.J., Shikami M., Cabreira-Hansen M., McQueen T., Ruvolo V., Tsao T., Zeng Z., Vassilev L.T., Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005, 106:3150-3159.
110. Renouf B., Hollville E., Pujals A., Tétaud C., Garibal J., Wiels J. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells. Leukemia 2009, 23:1557-1563.
111. Drakos E., Thomaides A., Medeiros L.J., Li J., Leventaki V., Konopleva M., Andreeff M., Rassidakis G.Z. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin. Cancer Res. 2007, 13:3380-3387.
112. Janz M., Stühmer T., Vassilev L.T., Bargou R.C. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Leukemia 2007, 21:772-779.
113. D'Arcy P., Ryan B.A., Brodin B. Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction. Cancer Lett. 2009, 275:285-292.
114. Bauer S., Mühlenberg T., Leahy M., Hoiczyk M., Gauler T., Schuler M., Looijenga L. Therapeutic potential of MDM2 inhibition in malignant germ cell tumours. Eur. Urol. 2010, 57:679-687.
115. Li B., Cheng Q., Li Z., Chen J. P53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. Cell Cycle 2010, 9:1411-1420.
116. Ray-Coquard I., Blay J.Y., Italiano A., Le Cesne A., Penel N., Zhi J., Heil F., Rueger R., Graves B., Ding M., Geho D., Middleton S.A., Vassilev L.T., Nichols G.L., Bui B.N. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012, 13:1133-1140.
117. Andreeff M., Kelly K.R., Yee K., Assouline S., Strair R., Popplewell L., Bowen D., Martinelli G., Drummond M.W., Vyas P., Kirschbaum M., Iyer S.P., Kojima K., Geho D., Blotner S., Cheng S., Vassilev L., Ding M., Zhi J., Middleton S., Nichols G. Results of the phase 1 trial of RG7112, a small-molecule MDM2 antagonist, in acute leukemia. Blood 2012, 120. Abstract 675.
118. Q. Ding, Z. Zhang, J.J. Liu, N. Jiang, J. Zhang, T.M. Ross, X.J. Chu, D. Bartkovitz, F. Podlaski, C. Janson, C. Tovar, Z.M. Filipovic, B. Higgins, K. Glenn, K. Packman, L.T. Vassilev, B. Graves, Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development, J. Med. Chem. (published online ahead of print July 16, 2013).